Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575
This study is recruiting at 16 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Acute Gout Flare
- Gout Attack
- Gout Flare
- Gouty Arthritis
- Gout
- Arthritis
- Joint Pain
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Olatec Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- March 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Arizona Arthritis & Rheumatology Associates - Glendale · Glendale, AZ
- Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa · Mesa, AZ
California · 2
- TriWest Research Associates · San Diego, CA
- Valiance Clinical Research - Tarzana · Tarzana, CA
Florida · 5
- Hillcrest Medical Research · DeLand, FL
- SIMEDHealth · Gainesville, FL
- University of Florida Health Jacksonville · Jacksonville, FL
- Well Pharma Medical Research · Miami, FL
- Clinical Research of West Florida · Tampa, FL
Georgia · 1
- Arthritis Center of North Georgia - Gainesville · Gainesville, GA
Illinois · 1
- Advanced Quality Medical Research · Orland Park, IL
Montana · 1
- Montana Medical Research · Missoula, MT
South Carolina · 1
- Lower Country Rheumatology - Summerville · Summerville, SC
Texas · 1
- Amarillo Center of Clinical Research · Amarillo, TX
Utah · 1
- Utah Health - University of Utah Hospital · Salt Lake City, UT
Washington · 1
- Arthritis Northwest · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.